The Flemish Government Selects DXC to Help Drive Transformation of Public Services
25.5.2021 21:20:00 EEST | Business Wire | Press release
DXC Technology (NYSE: DXC) announced today that it has been awarded a new 7-year IT services agreement extension by the Flemish Government, to continue supporting the Government’s transformation journey and efforts to respond to citizens’ needs through innovative and reliable public services. As the volume of transactions increases with more consumer-driven demands for information, DXC will help the Flemish Government to lower total costs and improve mainframe operations, security, performance, capacity and processing efficiency.
DXC’s expertise and capabilities across the Enterprise Technology Stack will enable DXC to build, run and operate modern application services in a hybrid cloud infrastructure for the Flemish Government. The goal is to l simplify the work of the public sector and support the Government to provide efficient, safe and easy-to-use digital public services, re-imagine the customer experience for citizens and businesses, and deliver more effectively on the public’s needs.
The contract extension is an opportunity for DXC to continue to deliver excellence and build on recent successful projects that Flanders citizens really care about; such as the “Corona Hinderpremie” for processing payment claims as well as “Vaccinnet”, a program for ordering vaccines in the health sector which DXC supported with training and user adoption to ensure a timely launch.
The Flemish Government and DXC have been working together for 18 years on diverse public sector projects and the contract extension reaffirms the strong relationship and confidence the Government has in the new DXC as a reliable IT partner.
Barbara Van Den Haute, administrateur-generaal at the Flemish Government: “We are focused on the modernisation of our public services and are glad to continue that work in collaboration with DXC Technology. We are striving to push forward, together, our IT transformation to develop innovative projects that will improve, simplify, and accelerate our services for citizens, businesses, and associations; should they be related to health, environmental or economic issues.”
“The Government of Flanders is a valued DXC customer. We are thrilled to extend our collaboration for the next seven years, bringing to bear our capabilities across the Enterprise Technology Stack in order to help the Flemish Government realize their strategic ambitions,” said Steve Turpie, Senior VP—EMEA, DXC Technology. ”We are committed to the Government’s program and to deliver innovative, cost-effective and timely technology solutions to the business community and citizens.”
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005892/en/
Contact information
Antonio Carril, Marketing & Communications, Belux, +32476228587, antonio.carril@dxc.com
Louise Preedy
,
Marketing & Communications, Southern Europe, lpreedy@dxc.com
Antoine Roussel
,
Marketing & Communications, Southern Europe, aroussel@dxc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom